User Fee Bills: After Mark-ups, How Will House And Senate Reconcile Differences?
Executive Summary
House and Senate committee user fee bill mark-ups approaching, but drafts have differences in drug shortage, supply chain security and other proposed policy changes to reconcile.
You may also be interested in...
Conflict of Interest Reform: Greatest Impact May Be Committee Vacancy Rate
FDA user fee reauthorization eliminates limits on waivers, which may ease the burden on FDA to fill open seats on its advisory committees. Vacancy rates have been as high as 24% in FY 2012.
Drug Shortages Proposal From Sen. Hatch Offers 7-Year Economic Incentives
The Utah Republican’s draft bill would encourage industry to increase its capacity to manufacture sterile injectable drug products by providing higher reimbursement rates and exclusivity incentives. House Republicans continue to pursue economic options, but time and jurisdictional factors could work against such measures to address shortages.
CBO Says Senate User Fee Package Will Decrease Direct Spending
While drug development incentives will increase federal health care program spending, other provisions designed to allow lower-cost drugs on the market faster are expected to reduce costs.